Serum IgM anti-GM1 ganglioside antibodies in lower motor neuron syndromes

European Journal of Neurology

Volumn 11, Issue 1, 2004, Pages 13-16

  Niebroj Dobosz, I ^a,b   Janik, P ^a   Kwiecinski H ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Autoimmunity; GM1 ganglioside antibodies; Lower motor neuron syndromes

Indexed keywords

GANGLIOSIDE GM1; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M ANTIBODY;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LOWER MOTONEURON DISEASE; MALE; MOTOR NEURON DISEASE; MOTOR NEUROPATHY; NERVE BLOCK; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; AUTOANTIBODIES; AUTOIMMUNITY; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; G(M1) GANGLIOSIDE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; NEUROMUSCULAR DISEASES;

EID: 0842286887     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1351-5101.2003.00697.x     Document Type: Article

References (28)

1. Adams D, Kuntzer T, Burger D et al. (1991). Predictive value of anti-GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera. J Neuroimmunol 32:223-230.
2. Alaedini A, Sander HW, Hays AP et al. (2003). Antiganglioside antibodies in multifocal acquired sensory and motor neuropathy. Arch Neurol 60:42-46.
3. Baba H, Daune GC, Ilyas AA et al. (1989). Anti-GM1 ganglioside antibodies with differing fine specificities in patients with multifocal motor neuropathy. J Neuroimmunol 25:143-150.
4. Feldman EL, Bromberg MB, Albers JW et al. (1991). Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 30:397-401.
5. Gallardo E, Rojas-Garcia R, Belvis R et al. (2001). Antigan-glioside antibodies: when, which and for what. Neurologia 16:293-297.
6. Gorgani NN, Parish CR, Altin JG (1999). Differential binding of histidine-rich glycoprotein (HRG) to human IgG subclasses and IgG molecules containing kappa and lambda light chains. J Biol Chem 274:29633-29640.
7. Lamb NL, Patten BM (1991). Clinical correlations of anti-GM1 antibodies in amyotrophic lateral sclerosis. Muscle Nerve 14:1021-1027.
8. Lange DJ, Trojaborg W, Latov N et al. (1992). Multifocal motor neuropathy with conduction block: is it a distinct clinical entity? Neurology 42:497-505.
9. Latov N, Hays AP, Donofrio PD et al. (1988). Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b. Neurology 38:763-768.
10. Niebroj-Dobosz I, Jamrozik Z, Janik P et al. (1999). Anti-neural antibodies in serum and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients. Acta Neurol Scand 100:238-243.
11. O'Hanlon GM, Paterson GJ, Veitch J et al. (1998). Mapping immunoreactive epitopes in the human peripheral nervous system using human monoclonal anti-GM1 ganglioside antibodies. Acta Neuropathol 95:605-616.
12. Parry GJ (1994). Antiganglioside antibodies do not necessarily play a role in multifocal motor neuropathy. Muscle Nerve 17:97-99.
13. Pestronk A (1991). Invited review: motor neuropathies, motor neuron disorders, and antiglycolipid antibodies. Muscle Nerve 14:927-936.
14. Pestronk A (1998). Multifocal motor neuropathy: diagnosis and treatment. Neurology 51(Suppl. 5):S22-S24.
15. Pestronk A, Choksi R (1997). Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology 49:1289-1292.
16. Pestronk A, Adams RN, Clawson RN et al. (1988). Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology 38:1457-1461.
17. Pestronk A, Chaudhry V, Feldman EL et al. (1990). Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antyglycolipid antibodies. Ann Neurol 27:316-326.
18. Pestronk A, Choksi R, Blume G, Lopate G (1997). Multifocal motor neuropathy: serum IgM binding to a GM1 ganglioside-containing lipid mixture but not to GM1 alone. Neurology 48:1104-1106.
19. Pilstrom L (2002). The mysterious immunoglobulin light chain. Dev Comp Immunol 26:207-215.
20. Quattrini A, Lorenzetti I, Sciorati C et al. (2001). Human IgM anti-GM1 autoantibodies modulate intracellular calcium homeostasis in neuroblastoma cells. J Neuroimmunol 114:213-219.
21. Sadiq SA, Thomas FP, Kilidireas K et al. (1990). The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology 40:1067-1072.
22. Santoro M, Thomas FP, Fink ME et al. (1990). IgM deposits at nodes Ranvier in a patient with amyotrophic lateral sclerosis, anti-GM1 antibodies, and multifocal motor conduction block. Ann Neurol 28:373-377.
23. Serratrice G (1993). Neuropathies motrices avec anticorps antiglycolipides. Presse Med 22:705-707.
24. Shy ME, Heiman-Patterson T, Parry GJ et al. (1990). Lower motor neuron disease in a patient with autoantibodies against gal(β1-3)galNAc in gangliosides GM1 and GD1b: improvement following immunotherapy. Neurology 40:842-844.
25. Song MK, Oh MS, Lee JH (2000). Light chain of natural antibody plays a dominant role in protein antigen binding. Biochem Biophys Res Comm 268:390-394.
26. Sun M, Li L, Gao QS, Paul S (1994). Antigen recognition by an antibody light chain. J Biol Chem 269:734-738.
27. Takigawa T, Yasuda H, Kikkawa R et al. (1995). Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol 37: 436-442.
28. Tan E, Lynn J, Amato A et al. (1994). Immunosuppresive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder. Arch Neurol 51:194-200.